
Commentary|Videos|May 30, 2025
CMSC Live: 2025 Annual Meeting Day 2
Host Jeffrey Wilken, PhD, chats with Anthony Feinstein, MPhil, PhD, FRCP, about the second day of the 2025 CMSC Annual Meeting in Phoenix, Arizona.
Advertisement
Host
- Jeffrey Wilken, PhD
President-Elect,Consortium of Multiple Sclerosis Centers (CMSC); assistant professor of neurology, Georgetown University; director of Research, Neuropsychology Associates of Fairfax; executive director, Washington Neuropsychology Research Group
Guest
- Anthony Feinstein, MPhil, PhD, FRCP
Professor of Psychiatry at the University of Toronto
Segment Breakdown
- 00:00 – Jeffrey Wilken, PhD, introduces Anthony Feinstein, MPhil, PhD, FRCP, and the topic of his Donald Paty lecture on depression in MS.
- 02:00 – Anthony Feinstein, MPhil, PhD, FRCP, notes the lack of sex-based differences in MS depression and absence of a genetic link, contrasting with general population trends.
- 04:00 – Structural and functional imaging show limbic system changes in patients with MS who are depressed, offering biological explanations for depression independent of life circumstances.
- 05:00 - Anthony Feinstein, MPhil, PhD, FRCP, highlights 2 promising drug and discusses strong evidence for internet-based CBT as well as the growing role of digital mental health tools.
- 07:30 - Anthony Feinstein, MPhil, PhD, FRCP, recommends combining therapy and medication, borrowing from general psychiatry, and notes that most patients with MS prefer psychotherapy, aligning with global mental health trends.
- 9:00 - Depression often goes undiagnosed or untreated in MS clinics and nurses or family members may notice depression first because of time-limited neurology visits.
- 10:30 - Anthony Feinstein, MPhil, PhD, FRCP, praises the meeting’s behavioral health focus and upcoming sessions on cognitive wellness and brain health. Emphasizes a shift toward supporting patient resilience and well-being, accelerated by the pandemic.
- 11:30 - Jeffrey Wilken, PhD, thanks Anthony Feinstein, MPhil, PhD, FRCP, for his lecture and conversation.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Phase 1b Trial for Solid Biosciences’ Friedreich Ataxia Gene Therapy SGT-212 Doses First Patient
2
Efficacy and Safety Data for Tavapadon as an Emerging Therapy in Parkinson’s Disease
3
Phase 3 VALOR Data Further Support Tofersen’s Impact on ALS Disease Progression, Survival
4
Efgartigimod Application Submitted for Seronegative gMG, EC Approves High-Dose Nusinersen, Copper Histidinate Gains First Approval for Menkes Disease
5




























